Due to biological complexity, many solid tumors represent a significant challenge to treatment. The OSF Breakthrough Treatment Center and its global partners are studying potentially game-changing ways to overcome these challenges.
C’Dot-Drug-Conjugates (CDCs)are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs).
This research will hopefully unlock enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.